Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
The role of ifosfamide in the treatment of relapsed and refractory lymphoma
Autore:
Reiser, M; Bredenfeld, H; Engert, A; Diehl, V;
Indirizzi:
Univ Cologne, Innere Med Klin 1, D-50924 Cologne, Germany Univ Cologne Cologne Germany D-50924 ed Klin 1, D-50924 Cologne, Germany
Titolo Testata:
EUROPEAN JOURNAL OF HAEMATOLOGY
, volume: 66, anno: 2001, supplemento:, 64
pagine: 37 - 40
SICI:
0902-4441(200107)66:<37:TROIIT>2.0.ZU;2-C
Fonte:
ISI
Lingua:
ENG
Soggetto:
NON-HODGKINS-LYMPHOMA; PREVIOUSLY TREATED PATIENTS; LEUKEMIA GROUP-B; PHASE-II TRIAL; SALVAGE CHEMOTHERAPY; COMBINATION CHEMOTHERAPY; ETOPOSIDE; REGIMEN; MITOXANTRONE; THERAPY;
Keywords:
DIZE; ifosfamide; refractory lymphoma; combination chemotherapy; salvage therapy;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Clinical Medicine
Life Sciences
Citazioni:
33
Recensione:
Indirizzi per estratti:
Indirizzo: Reiser, M Univ Cologne, Innere Med Klin 1, Joseph Stelzmann Str 9, D-50924Cologne, Germany Univ Cologne Joseph Stelzmann Str 9 Cologne Germany D-50924 any
Citazione:
M. Reiser et al., "The role of ifosfamide in the treatment of relapsed and refractory lymphoma", EUR J HAEMA, 66, 2001, pp. 37-40

Abstract

Ifosfamide is an alkylating agent with proven efficacy in the treatment ofsolid tumours and malignant lymphomas. Because it causes only mild to moderate myelosuppression, ifosfamide is often used in combination regimens with other agents, Ifosfamide has been mainly used in therapy of lymphoma as acomponent of salvage regimens, but high-dose ifosfamide is also effective in the mobilization of peripheral stem cells for treatment of patients withrelapsed or refractory lymphoma with regimens containing autologous stem cell transplantation. Based on promising data with a new combination regimencontaining idarubicin, etoposide and ifosfamide (IIVP-16) in patients withpoor-risk non-Hodgkin's lymphoma, we have performed a phase II study usingDIZE (dexamethasone 20 mg i.v. days 1-4, idarubicin 8 mg/m(2) i.v. days 1+2, ifosfamide 1.0 g/m(2) continuous infusion (c.i.) days 1-4, and etoposide160 mg/m(2) c.i. days 1-4) in patients with relapsed or refractory Hodgkin's and non-Hodgkin's lymphoma. In 43 evaluable patients, the response rate was 58%, including 11 complete remissions (CR) and 14 partial remissions (PR). The mean duration of response was 8 months (1-30). Myelosuppression wasgenerally mild with mean duration of neutropenia < 1000/muL of 2.5 days (range 0-18) and thrombocytopenia < 25 000/muL of 1.5 days (0-17). Thus, DIZEis an effective and safe regimen for pretreated patients with aggressive lymphoma. These results appear to compare favourably with other salvage regimens such as IMVP-16 or DHAP. In conclusion, salvage regimens containing ifosfamide can play an important role in patients who are not eligible fur high-dose chemotherapies. Moreover, ifosfamide might also have a role in reducing tumour burden and selecting those patients who qualify for HDCT.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 01/04/20 alle ore 10:48:06